Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
John F. Seymour(The Royal Melbourne Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Monali Desai(AbbVie (United States)), Constantine S. Tam(The Alfred Hospital), Thomas J. Kipps(University of California San Diego), Danielle M. Brander(Duke University), Leanne Lash(AbbVie (United States)), Betty Prine(AbbVie (United States)), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Suresh Agarwal(Boston Medical Center), Jacqueline C. Barrientos(Mount Sinai Medical Center), Michael Y. Choi(University of California San Diego), Shuo Ma(Nantong University), Wijith Munasinghe(AbbVie (United States)), Ming Zhu(AbbVie (United States)), Anne Beaven(Duke Medical Center), Mary Ann Anderson(The Royal Melbourne Hospital), Su Young Kim(Yonsei University), Gary Gordon, Elisa Cerri(AbbVie (United States)), Maria Verdugo(AbbVie (United States)), Steven T. Rosen(Unknown)
Cited by 327
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k